Posted by Michael Wonder on 03 Apr 2019
Cigna’s Express Scripts PBM to cap insulin costs amid drug price scrutiny
3 April 2019 - Cigna and its Express Scripts pharmacy benefit management unit Wednesday said they are rolling out a new program to cap out-of-pocket costs at $25 per 30 day insulin prescriptions for “non-government funded” drug plans.
The Patient Assurance Program, which is optional for Express Scripts clients to adopt, comes ahead of a high-profile Senate Finance Committee hearing scheduled for next week.
At the hearing, executives are scheduled to testify from Cigna, the Caremark PBM unit of CVS Health, UnitedHealth Group’s OptumRx PBM, health insurer Humana, which operates a large PBM, and Prime Therapeutics, a PBM owned by several Blue Cross and Blue Shield plans.
